Related Experiment Video
Updated: Aug 14, 2025

Wireless Telemetry Device Implantation in a Fontan Ovine Model for Continuous and Long-Term Hemodynamic Monitoring
Published on: May 2, 2025
Fontan Hepatopathy-Managing Unknowns
Dominica Zentner1, Khoa Phan2, Alexandra Gorelik3
1Department of Medicine (RMH), Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Vic, Australia; Department of Cardiology, Royal Melbourne Hospital, Melbourne, Vic, Australia.
Insights
Monitoring Fontan-associated liver disease (FALD) in adults is challenging. Acoustic Radiation Force Impulse imaging (ARFI) can indicate cirrhosis and guide hepatocellular carcinoma surveillance, but serial ARFI offers no clear benefit once cirrhosis is established.
Area of Science:
- Cardiology
- Hepatology
- Medical Imaging
Background:
- Fontan-associated liver disease (FALD) monitoring in adults requires optimized strategies.
- A prospective liver care pathway was implemented for 84 adults with Fontan circulation.
Purpose of the Study:
- To evaluate the utility of Acoustic Radiation Force Impulse imaging (ARFI) in monitoring FALD.
- To assess the correlation between ARFI, clinical endpoints, and patient characteristics.
Main Methods:
- Prospective monitoring of 84 adults with Fontan circulation.
- Liver assessment using ARFI and ultrasound.
- Collated data included liver biochemistry, ventricular function, and clinical outcomes (varices, HCC, transplantation, death).
Main Results:
- Most patients showed cirrhotic range ARFI results.
- ARFI values correlated with hepatic nodularity and inversely with platelet count.
- Clinical endpoints were more frequent in patients with ventricular dysfunction.
Conclusions:
- ARFI serves as a useful non-invasive indicator for cirrhosis in FALD.
- ARFI can identify patients needing closer hepatocellular carcinoma surveillance.
- Serial ARFI measurements do not provide additional benefit once cirrhosis is detected.
Background And Aims:
How to best monitor Fontan-associated liver disease (FALD) remains unclear. We describe results from a prospective liver care pathway in adults (n=84) with a Fontan circulation.
Methods:
Routine assessment of the liver, by acoustic radiation force frequency and ultrasound was undertaken. Results, including liver biochemistry, systemic ventricular function (echocardiography), functional class, medication use and clinical endpoints (varices, hepatocellular carcinoma, heart transplantation and death) were collated.
Results:
Most individuals returned a cirrhotic range acoustic radiation force impulse imaging (ARFI) result. ARFI values were greater in the proportion of individuals with hepatic nodularity (p=0.024). Univariate analysis demonstrated moderate correlation with platelet number (Spearmans rho= -0.376, p=0.049). Patients with clinical endpoints had lower platelets (p=0.012) but only a trend to hepatic nodularity (p=0.057). Clinical endpoints were more common in those with ventricular dysfunction (p=0.011). Multivariate analysis revealed that age at Fontan and being on angiotensin converting enzyme inhibitors (ACEI) predicted ARFI score (β=0.06 [95% CI 0.01-0.09], p=0.007 and β=0.53 [95% CI 0.17-0.89], p=0.005, respectively). However, these associations were not significant once adjusted for Fontan type, age at ARFI, systemic ventricle morphology, ventricle function, or Model for End-stage Liver Disease (MELD-XI) excluding international normalised ratio (INR) (p>0.05 for all).
Conclusions:
Ideal FALD monitoring remains unclear. ARFI has utility as a binary non-invasive indicator of cirrhosis, highlighting individuals who may need more frequent ongoing monitoring for hepatocellular carcinoma. However, no definite advantage to serial ARFI, once cirrhotic range ARFI results are present, has been identified.
More Related Videos
Related Concept Videos
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Heart Failure VI: Adjunct Therapies
Chronic Pancreatitis II: Collaborative Care
Assessment:
Mitral Regurgitation IV: Nursing Management
Heart Failure V: Medical Management
Mitral Stenosis IV: Nursing Management

